<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04849728</url>
  </required_header>
  <id_info>
    <org_study_id>337HNAS20011</org_study_id>
    <nct_id>NCT04849728</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis</brief_title>
  <acronym>NATiV3</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inventiva Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inventiva Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver&#xD;
      fibrosis stage 2 or 3&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objectives&#xD;
&#xD;
      This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver&#xD;
      fibrosis stage 2 or 3 and consists of 2 parts - Part 1 and Part 2, with the following primary&#xD;
      objectives:&#xD;
&#xD;
      Part 1 To assess the effect of lanifibranor compared to placebo on NASH resolution and&#xD;
      improvement of fibrosis assessed by liver histology.&#xD;
&#xD;
      Part 2 To assess the effect of lanifibranor compared to placebo on delaying NASH disease&#xD;
      progression measured by a composite endpoint that includes progression to cirrhosis,&#xD;
      liver-related clinical outcome events, or all-cause death.&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
      Key secondary objectives of Part 1:&#xD;
&#xD;
        -  To assess the effect of lanifibranor compared to placebo on NASH resolution and no&#xD;
           worsening of fibrosis&#xD;
&#xD;
        -  To assess the effect of lanifibranor compared to placebo on improvement of fibrosis with&#xD;
           no worsening of NASH&#xD;
&#xD;
      Other secondary objectives of both Part 1 and Part 2:&#xD;
&#xD;
        -  To assess the effect of lanifibranor compared to placebo on other key histological&#xD;
           features of NASH&#xD;
&#xD;
        -  To assess the effect of lanifibranor compared to placebo on NASH resolution and&#xD;
           improvement of fibrosis in diabetic patients&#xD;
&#xD;
        -  To assess the effect of lanifibranor compared to placebo on liver function tests&#xD;
&#xD;
        -  To assess the effect of lanifibranor compared to placebo on glycaemic parameters&#xD;
&#xD;
        -  To assess the effect of lanifibranor compared to placebo on lipid parameters&#xD;
&#xD;
        -  To assess the effect of lanifibranor compared to placebo on liver stiffness&#xD;
&#xD;
        -  To assess the effect of lanifibranor compared to placebo on health-related quality of&#xD;
           life&#xD;
&#xD;
        -  To assess the long-term safety (up to 7 years) of lanifibranor&#xD;
&#xD;
        -  To assess population PK modeling of lanifibranor using sparse sampling scheme&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2021</start_date>
  <completion_date type="Anticipated">September 2028</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of NASH and improvement of fibrosis</measure>
    <time_frame>Part 1: Date of randomisation until the date of biopsy at Week 72</time_frame>
    <description>Part 1: Resolution of NASH and improvement of fibrosis at Week 72, defined by NASH CRN scores for ballooning of 0 and inflammation of 0 to 1, and fibrosis score ≥1 stage decrease compared to Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to first clinical outcome event</measure>
    <time_frame>Part 2: Date of randomisation until the End of Study (EoS) date approximately 7 years after first patient randomized</time_frame>
    <description>Part 2:&#xD;
Histological progression to cirrhosis (defined as histological confirmation of fibrosis score CRN F4)&#xD;
All-cause mortality&#xD;
Liver transplant&#xD;
Model for End-Stage Liver Disease (MELD) score ≥15&#xD;
New onset ascites requiring treatment&#xD;
Overnight hospitalisation due to hepatic decompensation event(s) including:&#xD;
Hepatic encephalopathy Grade ≥2 (as assessed by West Haven scale)&#xD;
Variceal bleeding&#xD;
Spontaneous bacterial peritonitis (assessed by positive culture or cell count)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Lanifibranor (IVA 337) (800 mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 Lanifibranor tablets 400mg + 1 Placebo to match tablet with food --&gt; once a day (quaque die, QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lanifibranor (IVA 337) (1200 mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 Lanifibranor tablets 400mg with food --&gt; once a day (quaque die, QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 Placebo to match tablets with food --&gt; once a day (quaque die, QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVA337</intervention_name>
    <description>A total of 2000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part 1 and Part 2.</description>
    <arm_group_label>Lanifibranor (IVA 337) (1200 mg/day)</arm_group_label>
    <arm_group_label>Lanifibranor (IVA 337) (800 mg/day)</arm_group_label>
    <other_name>Lanifibranor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A total of 2000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part 1 and Part 2.</description>
    <arm_group_label>Lanifibranor (IVA 337) (800 mg/day)</arm_group_label>
    <arm_group_label>Matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, aged ≥18 years at the time of signing informed consent&#xD;
&#xD;
          2. Upon central biopsy reading process: diagnosis of NASH according to the&#xD;
             Steatosis-Activity-Fibrosis (SAF):&#xD;
&#xD;
               1. Steatosis score ≥1&#xD;
&#xD;
               2. Activity score: A3 or A4&#xD;
&#xD;
               3. Fibrosis score: F2 or F3&#xD;
&#xD;
          3. Stable dose for the drugs listed below:&#xD;
&#xD;
               1. Antidiabetic treatment if glucagon-like peptide-1 receptor agonists (GLP1&#xD;
                  receptor agonists) or sodium-glucose co-transporter-2 inhibitors (SGLT2&#xD;
                  inhibitors): Stable dose for at least 3 months&#xD;
&#xD;
               2. Vitamin E (if at a dose ≥400 IU/day): Stable dose for at least 6 months&#xD;
&#xD;
               3. Statins: Stable dose for at least 3 months&#xD;
&#xD;
          4. All other chronically administered drugs must be stable for at least 3 months prior to&#xD;
             Screening&#xD;
&#xD;
          5. Weight stable for 6 months prior to Screening and between the qualifying liver biopsy&#xD;
             and Baseline (no more than 5% change for both periods)&#xD;
&#xD;
          6. Negative serum pregnancy test at study Screening for females of childbearing potential&#xD;
             confirmed by central laboratory. Females of childbearing potential must practice a&#xD;
             consistent and proper use of highly effective method of contraception throughout the&#xD;
             study and for 1 month after treatment discontinuation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Liver-related:&#xD;
&#xD;
          1. Documented causes of chronic liver disease other than NASH&#xD;
&#xD;
          2. Histologically documented liver cirrhosis (fibrosis stage F4)&#xD;
&#xD;
          3. History or current diagnosis of hepatocellular carcinoma HCC&#xD;
&#xD;
          4. History of or planned liver transplant&#xD;
&#xD;
          5. Positive human immunodeficiency virus (HIV) serology&#xD;
&#xD;
          6. ALT or AST &gt;5 × ULN&#xD;
&#xD;
          7. Abnormal synthetic liver function as defined by Screening central laboratory&#xD;
             evaluation&#xD;
&#xD;
          8. Haemoglobin &lt;110 g/L (11 g/dL) for females and &lt;120 g/L (12 g/dL) for males&#xD;
&#xD;
          9. Patient currently receiving any approved treatment for NASH or obesity&#xD;
&#xD;
         10. Current or recent history (&lt;5 years) of significant alcohol consumption&#xD;
&#xD;
         11. Treatment with drugs that may cause non-alcoholic fatty liver disease (NAFLD)&#xD;
             administered for at least 2 weeks within 12 months prior to qualifying liver biopsy&#xD;
&#xD;
             Glycaemia related:&#xD;
&#xD;
         12. HbA1c &gt;9% at Screening&#xD;
&#xD;
         13. Diabetes mellitus other than type 2&#xD;
&#xD;
         14. Current treatment with insulin&#xD;
&#xD;
         15. Previous or current treatment with PPAR-gamma agonists (thiazolidinediones [TZDs])&#xD;
&#xD;
             Obesity related:&#xD;
&#xD;
         16. Bariatric surgery: Restrictive procedures are allowed, if performed &gt;6 months prior to&#xD;
             the qualifying liver biopsy; malabsorptive procedures and procedures combining both&#xD;
             restrictive and malabsorptive methods are not allowed within 5 years of the qualifying&#xD;
             liver biopsy.&#xD;
&#xD;
             Cardiovascular related:&#xD;
&#xD;
         17. History of heart failure with reduced left ventricular ejection fraction (LVEF)&#xD;
&#xD;
         18. Atrial fibrillation requiring anticoagulation&#xD;
&#xD;
         19. Unstable heart failure&#xD;
&#xD;
         20. Uncontrolled hypertension at Screening (values &gt;160/100 mm Hg)&#xD;
&#xD;
             General safety:&#xD;
&#xD;
         21. Women currently breastfeeding&#xD;
&#xD;
         22. Previous exposure to lanifibranor&#xD;
&#xD;
         23. Participation in any clinical trial investigational medicinal product/device within 3&#xD;
             months from Screening or 5 half-lives from Screening, whichever is longer&#xD;
&#xD;
         24. Concomitant treatment with PPAR-alpha agonists (fibrates)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arun J Sanyal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VCU Health, Gastroenterology Hepatology and Nutrition, 1200 West Broad Street, Richmond VA23298, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sven Francque, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Gastroenterology and Hepatology, Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Cooreman, MD</last_name>
    <phone>380447500</phone>
    <phone_ext>+33</phone_ext>
    <email>info@inventivapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Digestive Health Specialist of the Southeast</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fomatmedicalresearch</name>
      <address>
        <city>Camarillo</city>
        <state>California</state>
        <zip>93011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Simon, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SC Clinical Research</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92844</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ban Doan, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palmetto Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>USPA Advance Concept Medical Research Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Genoma Research Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pro Live Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curtis Freedland, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansas Medical Clinic - Gastroenterology</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shekhar Challa, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ObjectiveGI - Northeast GI Research</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Myers, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Shore Gastroenterology</name>
      <address>
        <city>Westlake</city>
        <state>Ohio</state>
        <zip>44145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mousab Tabbaa, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Clinical Research Institute</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute/American Research Corporation</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Digestive Health Research of North Texas</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Morrison, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase III</keyword>
  <keyword>Nonalcoholic Steatohepatitis</keyword>
  <keyword>NASH</keyword>
  <keyword>Peroxisome proliferator-activated receptor (PPAR)</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

